TAZVERIK
Drug
Epizyme, Inc.,
Total Payments
$13.4M
Transactions
7,394
Doctors
2,861
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $5.4M | 2,111 | 1,239 |
| 2021 | $6.1M | 4,112 | 1,967 |
| 2020 | $1.9M | 1,171 | 617 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.1M | 1,172 | 90.4% |
| Honoraria | $967,453 | 647 | 7.2% |
| Food and Beverage | $134,484 | 4,926 | 1.0% |
| Consulting Fee | $74,114 | 3 | 0.6% |
| Grant | $50,000 | 1 | 0.4% |
| Education | $26,800 | 541 | 0.2% |
| Travel and Lodging | $26,108 | 102 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $9,500 | 2 | 0.1% |
Payments by Type
Research
$12.1M
1,172 transactions
General
$1.3M
6,222 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | Epizyme, Inc., | $5.2M | 0 |
| A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | Ipsen Biopharmaceuticals, Inc | $1.4M | 0 |
| A PHASE 1B/2 OPEN-LABEL STUDY EVALUATING TAZEMETOSTAT IN COMBINATION WITH ENZALUTAMIDE OR ABIRATERONE/PREDNISONE IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Epizyme, Inc., | $1.0M | 1 |
| A PHASE1B/3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAZEMETOSTAT IN COMBINATION WITH DOXORUBICIN AS FRONTLINE THERAPY FOR ADVANCED EPITHELIOID SARCOMA | Epizyme, Inc., | $807,277 | 0 |
| A PHASE 1B/2 OPEN-LABEL STUDY IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Epizyme, Inc., | $739,947 | 0 |
| A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES | Epizyme, Inc., | $611,401 | 0 |
| A PHASE 2, MULTICENTER STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN ADULT SUBJECTS WITH INI1-NEGATIVE TUMORS OR RELAPSED/REFRACTORY SYNOVIAL SARCOMA | Epizyme, Inc., | $475,740 | 0 |
| A PHASE I, OPEN-LABEL SINGLE-DOSE PHARMACOKINETIC AND SAFETY STUDY OF ORAL TAZEMETOSTAT IN SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT WITH ADVANCED MALIGNANCIES | Epizyme, Inc., | $435,003 | 0 |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial | Ipsen Biopharmaceuticals, Inc | $354,920 | 0 |
| A PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY INI1-NEGATIVE TUMORS OR SYNOVIAL SARCOMA | Epizyme, Inc., | $300,032 | 0 |
| A Phase II Open-Label, Multicenter trial of oral Tazemetostat in combination with Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma | Epizyme, Inc., | $249,916 | 0 |
| A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research | Epizyme, Inc., | $166,251 | 0 |
| A PHASE 2, MULTICENTER STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY MALIGNANT MESOTHELIOMA WITH BAP1 LOSS OF FUNCTION | Epizyme, Inc., | $113,579 | 0 |
| TAZEMETOSTAT ROLLOVER STUDY (TRUST): AN OPEN-LABEL, ROLLOVER STUDY | Epizyme, Inc., | $90,573 | 0 |
| A STUDY OF ORAL TAZEMETOSTAT IN SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT WITH ADVANCED MALIGNANCIES | Epizyme, Inc., | $32,272 | 0 |
| EZH-108 | Epizyme, Inc., | $25,093 | 0 |
| EZH-301 | Epizyme, Inc., | $21,761 | 0 |
| EZH-202 | Epizyme, Inc., | $2,290 | 0 |
| EZH-501 | Epizyme, Inc., | $849.33 | 0 |
| SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma | Epizyme, Inc., | $300.00 | 0 |
Top Doctors Receiving Payments for TAZVERIK
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Angelica Singh | — | Brooklyn, NY | $12.2M | 1,179 |
| , MD | Medical Oncology | Dallas, TX | $78,741 | 63 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $41,453 | 39 |
| , MD | Hematology | Sioux Falls, SD | $36,262 | 28 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $29,539 | 23 |
| , M.D. , M.P.H | Hematology & Oncology | Albany, NY | $29,182 | 28 |
| , MD | Hematology & Oncology | Orlando, FL | $25,515 | 28 |
| , M.D | Medical Oncology | Bethesda, MD | $24,504 | 19 |
| , M.D | Hematology | Hackensack, NJ | $24,351 | 20 |
| , MD | Medical Oncology | Bolivar, MO | $23,457 | 33 |
| , M.D | Hematology & Oncology | Houston, TX | $22,996 | 26 |
| , M.D | Hematology & Oncology | Albany, NY | $20,500 | 5 |
| Andrew Whiteley | Internal Medicine | Dallas, TX | $16,155 | 15 |
| , M.D | Medical Oncology | Spokane, WA | $15,614 | 10 |
| , M.D | Hematology & Oncology | New York, NY | $15,579 | 9 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $15,075 | 18 |
| , MD | Internal Medicine | Wichita, KS | $14,984 | 19 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $12,874 | 13 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Altamonte Springs, FL | $12,389 | 14 |
| , MD | Hematology & Oncology | San Diego, CA | $11,766 | 14 |
| , M.D | Hematology & Oncology | Tampa, FL | $9,997 | 9 |
| , MD | Internal Medicine | Buffalo, NY | $9,804 | 7 |
| , MD | Medical Oncology | Philadelphia, PA | $9,735 | 4 |
| , M.D | Hematology & Oncology | New York, NY | $9,441 | 6 |
| , APRN | Nurse Practitioner | Wethersfield, CT | $8,825 | 27 |
Ad
Manufacturing Companies
- Epizyme, Inc., $11.6M
- Ipsen Biopharmaceuticals, Inc $1.8M
Product Information
- Type Drug
- Total Payments $13.4M
- Total Doctors 2,861
- Transactions 7,394
About TAZVERIK
TAZVERIK is a drug associated with $13.4M in payments to 2,861 healthcare providers, recorded across 7,394 transactions in the CMS Open Payments database. The primary manufacturer is Epizyme, Inc.,.
Payment data is available from 2020 to 2022. In 2022, $5.4M was paid across 2,111 transactions to 1,239 doctors.
The most common payment nature for TAZVERIK is "Unspecified" ($12.1M, 90.4% of total).
TAZVERIK is associated with 20 research studies, including "A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA" ($5.2M).